Dengue Vaccine Shortage Grips Buenos Aires Region
Buenos Aires residents are facing a worrying shortage of QDenga, the only authorized dengue vaccine, with pharmacies across the Pergamin region reporting empty shelves for months. The scarcity has left many without immunization or a second dose, exacerbating concerns about the spread of the virus in the vulnerable region.
"We believe the lab ran out of production due to massive purchases by the provincial government and Buenos Aires City," explained Raquel Speranza, president of the Pergamin College of Pharmacists. This surge in demand has outpaced supply, creating a critical shortage for the general public.
Adding to the difficulty, the price of QDenga has increased from 97,962 to 102,812 pesos per dose, highlighting a significant financial burden for those seeking protection. While some prepaid healthcare plans offer partial coverage, others provide no assistance, further widening the gap in access.
Despite the lack of available doses, the Argentinian Ministry of Health is pushing forward with its public vaccination program. According to official data, 42% of eligible individuals in Health Region IV have received both doses.
However, the program faces challenges in reaching all those who need it. Many residents who have had dengue but were treated at private labs lack official registration in the unified health registry. This exclusion underscores the importance of a seamless data sharing system between public and private healthcare providers.
Efforts to Increase Access:
To address this, the Ministry of Health encourages individuals who have had dengue to register their diagnosis through Buenos Aires’ “My Health” portal: ms.gba.gov.ar/sitios/misalud/. This registration will ensure they can get vaccinated once the supply chain stabilizes.
Understanding QDenga:
Produced by Takeda Laboratory, QDenga is a live, attenuated quadrivalent vaccine requiring two doses spaced three months apart. It protects against all four dengue serotypes for individuals aged 4 and above, with no upper age limit.
Contraindications:
It’s crucial to note that the vaccine is not recommended for pregnant or breastfeeding women, immunocompromised individuals, or those undergoing chemotherapy or high-dose corticosteroid treatments.
A Call for Collaboration:
As the fight against dengue continues, strong collaboration between authorities, pharmacies, health providers, and the community are essential.
Frank communication about vaccine availability, addressing data sharing gaps, and working towards a robust and sustainable supply chain are crucial steps in ensuring that everyone in the Buenos Aires region has access to this vital protection.